clofutriben
Small molecule
Evidence outlook
Type 2 Diabetes: topline reported 2026-06-08
The sponsor reported topline results on 2026-06-08 (Phase 2 study NCT02372578 in type 2 diabetes: HbA1c, glucose and total cholesterol reduced versus placebo at 6 weeks). The announcement is listed under Regulatory events.
Also in development:Cushing's Syndrome · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
CAPTAIN-T2D NCT07296484 · Type 2 Diabetes, Cortisol Excess Registry: NCT07296484 | 2 | Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night. (8-10 hours after the dexamethasone 1 mg dose.); Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment. (24 weeks.) 2027-12-31 | In progress: results expected 31 Dec 2027 | not yet graded | link ↗ |
View 1 more trial
NCT05409027 NCT05409027 · Type 2 Diabetes Mellitus in Obese, Obesity, Type 2 Diabetes Everyone in the study received the same treatment with no control group and no blinding, and the goal was to measure drug levels and enzyme activity rather than a clinical benefit. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT05409027 | 1 | Pharmacokinetics (Cmax) (Days 1 through 14) 2022-03-10 | Clofutriben's HSD-1 activity was measured during daily oral administration with mass-labelled enzyme substrate infusion via microdialysis catheters in subcutaneous abdominal adipose of 12 persons with type 2 diabetes and obesity. During initial dosing, clofutriben was associated with dose-dependent decreases of mass-labelled HSD-1 product (cortisol) in adipose dialysate, from less than 25% at 1 mg to more than 90% at 6 to 10 mg. At steady state, all clofutriben doses were associated with more than 90% decreases with no evidence of tachyphylaxis. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other 11-beta-HSD1 drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Cushing's Syndrome: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Clofutriben: this drug | Phase 2 | Small molecule | 11-beta-HSD1 | not yet graded | No reviewed efficacy summary in this indication | |
| Mifepristone (Korlym) | Approved | Small molecule | Progesterone receptor; Glucocorticoid receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Relacorilant (Lifyorli) | Phase 3 | Small molecule | Glucocorticoid receptor | Partial signal | NCT04308590: Change in Average 24-hour SBP (Baseline and Week 22): Relacorilant -5.56 mm Hg (95% CI -10.459 to -0.659) vs Placebo -2.89 mm Hg (95% CI -6.794 to 1.006) missed | |
| Emestedastat (Xanamem) | Phase 2/3(overall) | Small molecule | 11-beta-HSD1 | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow clofutriben to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent